US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

Articles published by Pieris Pharmaceuticals, Inc.

News headline image
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Death
Tickers PIRS
News headline image
Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
News headline image
Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers PIRS
News headline image
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers PIRS
News headline image
Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers PIRS